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Summary Angiogenesis plays a pivotal role in nor-
mal ovarian physiology as well as in the formation and
progression of ovarian cancer. Several well-designed
phase II and III trials studied the efficacy of antiangio-
genic agents in advanced ovarian cancer. The results
of these trials demonstrated significantly prolonged
progression-free survival when antiangiogenic agents
were used as a maintenance therapy. To date, no ef-
fect on overall survival could be ascertained. The most
widely studied antiangiogenic agent, bevacizumab –
a monoclonal humanized antibody against vascular
endothelial growth factor – was effective in all phases
of the disease (first-line therapy, platinum-sensitive
and platinum-resistant recurrence). These results led
to regulatory approval in many countries including
the European Union. Other anti-VEGF agents such as
tyrosine kinase inhibitors have not shown increased
activity but increased toxicity relative to bevacizumab.
Agents targeting angiopoietin-1 and -2 are in develop-
ment and new combinations with PARP inhibitors and
immune checkpoint inhibitors are studied. This re-
view summarizes the current data and knowledge on
the clinical use of antiangiogenic agents in advanced
ovarian cancer.
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Introduction
Epithelial ovarian cancer (EOC) is the leading cause
of death from a gynecologic cancer. Currently there
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is no effective screening or early detection for this tu-
mor entity. Therefore, 70–80% of patients present at
an advanced stage at the time of diagnosis. Standard
therapy of advanced stage EOC is aggressive cytore-
ductive surgery with the aim of removing all visible
tumor followed by platinum- and taxane-containing
chemotherapy. With modern surgical interventions
and contemporary chemotherapy, most patients at-
tain complete clinical remission [1]. The majority of
them, however, will eventually relapse and die of the
disease. Therefore, additional therapeutic strategies
are needed to improve patient survival. Angiogenesis
has been established as a basic feature of tumor de-
velopment, growth, and spread beyond regional bor-
ders [2]. Vascular endothelial growth factor (VEGF),
which can be seen as the most prominent proangio-
genic molecule, has been shown to be an indepen-
dent prognostic parameter in patients with all stages
of ovarian cancer [3]. Among several antiangiogenic
compounds that have been developed, EOC proved
to be a tumor entity particularly sensitive to antian-
giogenic therapy. This review summarizes results of
clinical trials investigating the efficacy and role of an-
tiangiogenic therapies in advanced-stage EOC.
Antiangiogenic agents in the adjuvant therapy of
EOC
Bevacizumab
Bevacizumab (BEV) is a monoclonal humanized
antibody against VEGF. There are two randomized
placebo-controlled phase III trials that investigated
the efficacy of BEV in the adjuvant treatment of
advanced EOC [4, 5]. GOG (Gynecologic Oncology
Group) 218 was a double-blind, placebo-controlled,
phase III trial that randomized patients with newly di-
agnosed stage III (incompletely resectable) or stage IV
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EOC who had undergone debulking surgery. Pa-
tients were randomized into three treatment groups:
chemotherapy with paclitaxel plus carboplatin, for
cycles 1–6 plus placebo in cycles 2–22 (control arm);
chemotherapy plus BEV in cycles 2–6 and placebo
in cycles 7–22 (BEV initiation treatment arm); and
chemotherapy plus BEV in cycles 2–22 (BEV main-
tenance treatment arm). BEV was administered at
a dosage of 15 mg/kg body weight. The primary
endpoint of the study was progression-free survival
(PFS). In all, 1873 women were enrolled in the study.
The median PFS was 10.3 months in the control
arm, 11.2 months in the BEV initiation arm, and
14.1 months in the BEV maintenance arm. Relative
to control treatment, the hazard ratio for progression
or death was 0.908 (p = 0.16) with BEV initiation and
0.717 (p < 0.001) with BEV maintenance. There were
no significant differences in overall survival among the
three groups. The rate of hypertension requiringmed-
ical therapy was higher in the BEV initiation group
(16.5%) and the BEV maintenance group (22.9%)
than in the control group (7.2%). Gastrointestinal
wall disruption requiring medical intervention oc-
curred in 1.2%, 2.8%, and 2.6% of patients in the
control group, the BEV initiation group, and the BEV
maintenance group, respectively [4].
In ICON, seven women with EOC were randomly
assigned to carboplatin and paclitaxel given every
3 weeks for six cycles (control arm) and chemother-
apy plus BEV (7.5 mg/kg body weight) given con-
currently every 3 weeks for five or six cycles and
continued for 12 additional cycles or until progres-
sion of disease. Outcome measures were PFS and
overall survival. A total of 1528 women were ran-
domly assigned to one of the two treatment regimens:
9% had high-risk early-stage disease, 30% were at
high risk for progression, and 70% had stage IIIC or
IV EOC. PFS was 20.3 months with standard therapy
compared with 21.8 months, measured at 36 months,
with standard therapy plus BEV (p = 0.004). BEV was
associated with increased toxicity (mainly hyperten-
sion; 18% vs. 2% with chemotherapy alone). In the
updated analyses, PFS measured at 42 months was
22.4 months without BEV versus 24.1 months with
BEV (P = 0.04); in patients at high risk for progres-
sion, the benefit was greater with BEV than without
it, with PFS at 42 months of 14.5 months with stan-
dard therapy alone and 18.1 months with BEV added;
the respective median overall survival was 28.8 and
36.6 months, respectively. BEV used as a maintenance
therapy improved PFS in women with EOC. The ben-
efits with respect to PFS and overall survival seemed
to be greater among patients at high risk for disease
progression and more advanced disease. In an ex-
ploratory analysis of a predefined subgroup of 502
patients with poor prognosis, a significant difference
in overall survival was noted between women who
received BEV plus chemotherapy and those who re-
ceived chemotherapy alone (restricted mean survival
time 34.5 months with standard chemotherapy vs.
39.3 months with BEV; p = 0·03) [5].
Pazopanib
Pazopanib is an oral, tyrosine kinase inhibitor (TKI) of
vascular endothelial growth factor receptor (VEGFR)-
1/-2/-3, platelet-derived growth factor receptor
(PDGFR), and c-Kit. The AGO(Arbeitsgemeinschaft
Gynäkologische Onkologie)-OVAR 16 study evaluated
the role of pazopanib maintenance therapy in pa-
tients with EOC whose disease did not progress dur-
ing first-line chemotherapy. In this study, 940 patients
with histologically confirmed cancer of the ovary, fal-
lopian tube, or peritoneum, FIGO stages II–IV, no
evidence of progression after primary therapy con-
sisting of surgery and at least five cycles of platinum-
taxane chemotherapy were randomized 1:1 to re-
ceive pazopanib 800 mg once per day or placebo
for up to 24 months. The primary endpoint was
PFS. Maintenance pazopanib prolonged PFS com-
pared with placebo (median 17.9 vs. 12.3 months,
p = 0.0021). Overall survival did not show any sig-
nificant difference. Grade 3 or 4 adverse events in-
cluded hypertension (30.8%), neutropenia (9.9%),
liver-related toxicity (9.4%), diarrhea (8.2%), fatigue
(2.7%), thrombocytopenia (2.5%), and palmar-plan-
tar erythrodysesthesia (1.9%) and were significantly
higher in the pazopanib arm. Pazopanib maintenance
therapy significantly improved PFS in patients with
advanced EOC [6, 7].
Nintedanib
Nintedanib is an oral triple angiokinase inhibitor of
VEGFR, PDGFR, and fibroblast growth factor receptor.
In a double-blind phase III trial, chemotherapy-naive
patients with FIGO stage IIB–IV EOC and upfront
debulking surgery were stratified according to post-
operative resection status, FIGO stage, and planned
carboplatin dose. Patients were randomly assigned
(2:1) to receive six cycles of carboplatin and pa-
clitaxel in addition to either 200 mg of nintedanib
(nintedanib group) or placebo (placebo group) twice
daily on days 2–21 of every 3-week cycle for up to
120 weeks. The primary endpoint was investiga-
tor-assessed PFS analyzed in the intention-to-treat
population. In all, 1503 patients were screened and
1366 randomized: 486 (53%) of 911 patients in the
nintedanib group experienced disease progression
or death compared with 266 (58%) of 455 in the
placebo group. Median PFS was significantly longer
in the nintedanib group than in the placebo group
(17.2 months vs. 16.6 months, p = 0.024). The most
common adverse events were gastrointestinal (diar-
rhea grade 3/4: nintedanib group 22% vs. placebo
group 2%) and hematological (neutropenia grade
3/4: nintedanib group 42% vs. placebo group 36%;
thrombocytopenia: 18% vs. 7%; anemia: 13% vs.
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7%, respectively). Nintedanib in combination with
carboplatin and paclitaxel significantly increased PFS
for women with advanced EOC, but is associated with
more gastrointestinal adverse events [8].
Recurrent EOC
Platinum-sensitive EOC
In a randomized, blinded, placebo-controlled phase III
trial the efficacy and safety of BEV with gemcitabine
and carboplatin compared with gemcitabine and car-
boplatin in platinum-sensitive recurrent EOC was
studied (OCEANS trial). BEV-naive patients with
platinum-sensitive ovarian cancer (recurrence free
interval >6 months after front-line platinum-based
chemotherapy) and measurable disease were ran-
domly assigned to gemcitabine/carboplatin plus ei-
ther BEV or placebo for six to ten cycles. BEV was
administered at a dosage of 15 mg/kg body weight.
BEV or placebo was then continued until disease
progression. The primary endpoint was PFS by RE-
CIST (Response Evaluation Criteria In Solid Tumors).
Secondary endpoints were objective response rate,
duration of response, overall survival, and safety. In
total, 484 patients were randomized. PFS for the BEV
arm was superior to the placebo arm (median PFS
was 12.4 vs. 8.4 months, p > 0.0001). The objective
response rate (78.5% vs. 57.4%; p < 0.0001) and the
duration of response (10.4 vs. 7.4 months) were signif-
icantly higher with the addition of BEV. No new safety
concerns were noted. Gemcitabine/carboplatin plus
BEV followed by BEV until progression prolonged PFS
significantly compared with the placebo arm [9].
Cediranib is an oral antiangiogenic VEGFR 1–3 in-
hibitor. In ICON 6 – a randomized, three-arm, dou-
ble-blind, placebo-controlled phase III trial – the
efficacy and safety of cediranib in combination with
platinum-based chemotherapy and as maintenance
treatment in patients with platinum-sensitive recur-
rent EOC were assessed. Patients received up to six
cycles of platinum-based chemotherapy and then
entered a maintenance phase. Participants were ran-
domly allocated (2:3:3) to receive (a) placebo with
chemotherapy and as maintenance (control arm),
(b) cediranib 20 mg once daily with chemotherapy
then placebo as maintenance (concurrent arm), or
(c) cediranib 20 mg once daily with chemotherapy
and as maintenance (maintenance arm). Patients
continued treatment to progression or unacceptable
toxicity. The primary endpoint was PFS. Here, 456 pa-
tients were randomized and evaluated. Median PFS
was 11.0 months in the maintenance arm, 8.7 months
in the control arm (p < 0.0001), and 9.9 months in
the concurrent arm. Diarrhea, neutropenia, hyper-
tension, hypothyroidism, and voice changes were
significantly more common in the cediranib arms.
Of the patients, 10% experienced grade 3/4 diarrhea
during chemotherapy and cediranib therapy and 12%
during cediranib maintenance therapy. Cediranib
showed a significantly prolonged PFS in the mainte-
nance arm compared with the control arm, but was
associated with significantly increased toxicity [10].
Trebananib inhibits the binding of angiopoietins
1 and 2 to the Tie2 receptor, and thereby inhibits
angiogenesis. TRINOVA 1, a randomized, double-
blind phase III study, assessed whether the addition
of trebananib to single-agent weekly paclitaxel in
patients with recurrent EOC improved PFS. Patients
received weekly intravenous paclitaxel plus either
weekly placebo or trebananib (15 mg/kg). Patients
were stratified on the basis of platinum-free inter-
val. The primary endpoint was PFS, and 919 patients
were enrolled. Median progression-free survival was
significantly longer in the trebananib group than in
the placebo group (7.2 vs. 5.4 months, p < 0.0001).
Trebananib was associated with more adverse event-
related treatment discontinuations than was placebo
and with higher incidences of chronic, long-lasting
edema. Serious adverse events were recorded in 28%
vs. 34% of patients in the trebananib group. In-
hibition of angiopoietins 1 and 2 with trebananib
provided a significant prolongation of PFS [11].
Platinum-resistant EOC
AURELIA was a randomized phase III trial combining
BEV with chemotherapy in platinum-resistant ovarian
cancer. Eligible patients had measurable disease that
had progressed less than 6 months after completing
platinum-based therapy. Chemotherapy (pegylated
liposomal doxorubicin, weekly paclitaxel, or topote-
can) was chosen by the investigators. Patients were
randomized to single-agent chemotherapy alone or
in combination with BEV (10 mg/kg every 2 weeks or
15 mg/kg every 3 weeks) until progression and/or un-
acceptable toxicity. Single-agent BEV was permitted
after progression with chemotherapy alone. The pri-
mary endpoint was PFS. Median PFS was 3.4 months
with chemotherapy alone versus 6.7 months with
BEV-containing therapy. Overall response rate (ORR)
was 11.8% versus 27.3% (p < 0.001). No new safety
signals were observed. Adding BEV to chemotherapy
statistically significantly improved PFS and ORR [12].
Discussion
Antiangiogenic agents clearly showed efficacy in pa-
tients with advanced EOC in a large number of well-
designed phase III trials. BEV was the most inten-
sively studied antiangiogenic agent. Adding BEV to
chemotherapy and as a maintenance therapy led to
a significantly improved PFS in first-line treatment
as well as in platinum-sensitive and platinum-re-
sistant EOC. During and after adjuvant therapy, an
association has been shown between increasing dis-
ease severity and a stronger beneficial effect of BEV.
These observations suggest that a residual tumor
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burden, presumably producing VEGF, is necessary to
enable BEV to exert its effect on the tumor microenvi-
ronment. In patients with optimally cytoreduced ad-
vanced ovarian cancer, a later onset of BEV therapy
and/or an extended duration might therefore be more
effective.
TKIs also showed efficacy in the treatment of ovar-
ian cancer in terms of PFS and response rates. How-
ever, compared with BEV, TKIs have a less favorable
toxicity profile and therefore will probably lead to an
impaired patient adherence to these orally adminis-
tered drugs. Currently, none of the TKIs is approved
in the European Union.
Several issues are still to be addressed regarding
antiangiogenic therapy in EOC. The optimal duration
of therapy remains unclear. It seems that prolonged
administration of BEV (2 years) could improve PFS.
Currently there is one randomized phase III trial in-
vestigating this issue (BOOST trial).
Another topic is re-induction therapy after com-
plete response with an antiangiogenic agent.
Re-treatment with BEV after a prior BEV response
was associated with a significantly improved PFS [13].
The meaningful improvement (14 months) in PFS
strongly supports the re-use of BEV in subsequent
regimens in patients who demonstrate an initial re-
sponse to BEV. To clarify this issue, further clinical
trials are needed.
Furthermore, the evaluation of biomarkers predict-
ing the response to antiangiogenic therapies should
be investigated. There is clear molecular evidence
that ovarian cancer is a highly heterogeneous disease.
The five main immunohistological subtypes (high-
grade serous, endometrioid, clear cell, low-grade
serous, and mucinous) differ vastly in terms of stage,
chemosensitivity, overall survival, and driver genetic
mutations [14]. Despite these clear differences, most
clinical trials of antiangiogenesis therapy have been
performed with unselected patient populations. One
study as part of the ICON 7 trial demonstrated a dis-
criminatory signature comprising mesothelin, FLT4,
AGP, and CA-125 as potentially identifying patients
with EOC more likely to benefit from BEV. The results
require validation [15]. Molecular clustering showed
different subtypes of ovarian cancers (immune, an-
gio, angioimmune). Immune-type cancers seem to
be very sensitive to platinum chemotherapy and the
addition of BEV showed a negative impact on clinical
outcome [16].
In summary, improved patient selection and iden-
tification of patients who will benefit from antiangio-
genic therapy and those who will not are therefore of
utmost importance.
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